Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan

[thumbnail of brainsci-11-01583.pdf]
brainsci-11-01583.pdf - Published Version (3MB) | Preview
Available under license: Creative Commons Attribution

Matsoukas, John ORCID: 0000-0001-5554-2964, Ligielli, Irene, Chasapis, Christos T, Kelaidonis, Konstantinos, Apostolopoulos, Vasso ORCID: 0000-0001-6788-2771 and Mavromoustakos, Thomas (2021) Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan. Brain Sciences, 11 (12). ISSN 2076-3425


Multiple Sclerosis (MS) is a serious autoimmune disease. The patient in an advanced state of the disease has restrained mobility and remains handicapped. It is therefore understandable that there is a great need for novel drugs and vaccines for the treatment of MS. Herein we summarise two major approaches applied for the treatment of the disease using peptide molecules alone or conjugated with mannan. The first approach focuses on selective myelin epitope peptide or peptide mimetic therapy alone or conjugated with mannan, and the second on immune-therapy by preventing or controlling disease through the release of appropriate cytokines. In both approaches the use of cyclic peptides offers the advantage of increased stability from proteolytic enzymes. In these approaches, the synthesis of myelin epitope peptides conjugated to mannan is of particular interest as this was found to protect mice against experimental autoimmune encephalomyelitis, an animal model of MS, in prophylactic and therapeutic protocols. Protection was peptide-specific and associated with reduced antigen-specific T cell proliferation. The aim of the studies of these peptide epitope analogs is to understand their molecular basis of interactions with human autoimmune T-cell receptor and a MS-associated human leucocyte antigen (HLA)-DR2b. This knowledge will lead the rational design to new beneficial non-peptide mimetic analogs for the treatment of MS. Some issues of the use of nanotechnology will also be addressed as a future trend to tackle the disease. We highlight novel immunomodulation and vaccine-based research against MS based on myelin epitope peptides and strategies developed in our laboratories.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.3390/brainsci11121583
Official URL
Subjects Current > FOR (2020) Classification > 3204 Immunology
Current > Division/Research > Institute for Health and Sport
Keywords myelin epitope peptides; MBP87-99; MOG35-55; PLP139-151; Cyclization; conjugation with mannan; vaccines
Citations in Scopus 5 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login